Head-to-head · free

Nektar Therapeutics vs Nuwellis, Inc.

NKTR vs NUWE — return on capital, cash generation, margins and balance sheet side by side.

NKTR

4 / 9

measures where NKTR leads

NUWE

5 / 9

measures where NUWE leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNKTR · FY2025NUWE · FY2025
Revenue$55.2M$8.3M
Net income(164.1M)(17.5M)
Revenue growth (yearly, multi-year)23.6%1.1%
Free cash flow(208.7M)(10.9M)
Free cash flow margin-377.8%-131.8%
Net cash / (debt)——
ROIC——
Return on equity-217.9%-382.8%
Gross margin100.0%62.0%
Operating margin-236.8%-134.3%
Net debt / EBITDA0.11x0.10x

Figures are as reported by each company; latest fiscal year shown.

Where Nektar Therapeutics's cash went (FY2025)

Capital spending
$171000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NKTR profile →

Where Nuwellis, Inc.'s cash went (FY2025)

Capital spending
$90000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NUWE profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons